Texas Capital Bancshares Inc. TX Decreases Position in Johnson & Johnson (JNJ)

Texas Capital Bancshares Inc. TX cut its holdings in Johnson & Johnson (NYSE:JNJ) by 30.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,245 shares of the company’s stock after selling 985 shares during the period. Texas Capital Bancshares Inc. TX’s holdings in Johnson & Johnson were worth $292,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in JNJ. Usca Ria LLC lifted its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock worth $6,179,000 after acquiring an additional 2,244 shares during the last quarter. Willingdon Wealth Management lifted its holdings in shares of Johnson & Johnson by 11.8% in the first quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock worth $1,614,000 after acquiring an additional 1,372 shares during the last quarter. WASHINGTON TRUST Co lifted its holdings in shares of Johnson & Johnson by 2.3% in the first quarter. WASHINGTON TRUST Co now owns 108,714 shares of the company’s stock worth $13,540,000 after acquiring an additional 2,402 shares during the last quarter. GFS Advisors LLC raised its holdings in Johnson & Johnson by 9.8% in the 1st quarter. GFS Advisors LLC now owns 95,696 shares of the company’s stock valued at $11,919,000 after buying an additional 8,504 shares during the last quarter. Finally, Sfmg LLC raised its holdings in Johnson & Johnson by 0.8% in the 1st quarter. Sfmg LLC now owns 6,663 shares of the company’s stock valued at $830,000 after buying an additional 52 shares during the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

A number of brokerages recently issued reports on JNJ. Citigroup raised their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a report on Monday, October 30th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. BMO Capital Markets raised their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $165.00 price objective (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $145.47.

Johnson & Johnson (NYSE JNJ) opened at $140.12 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $144.35. The stock has a market cap of $376,440.00, a P/E ratio of 24.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.68 EPS. sell-side analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.

COPYRIGHT VIOLATION WARNING: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/12/25/texas-capital-bancshares-inc-tx-decreases-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit